Megan Rech
Concepts (437)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pharmacists | 19 | 2026 | 258 | 7.360 |
Why?
| | Blood Coagulation Factors | 11 | 2026 | 71 | 6.270 |
Why?
| | Emergency Medicine | 16 | 2026 | 282 | 5.210 |
Why?
| | Sepsis | 16 | 2025 | 664 | 4.870 |
Why?
| | Emergency Service, Hospital | 43 | 2026 | 2381 | 4.810 |
Why?
| | Anticoagulants | 12 | 2026 | 748 | 4.070 |
Why?
| | Shock, Septic | 10 | 2023 | 227 | 3.580 |
Why?
| | Pharmacy Service, Hospital | 8 | 2026 | 89 | 3.200 |
Why?
| | Factor Xa Inhibitors | 5 | 2026 | 194 | 3.020 |
Why?
| | Intracranial Hemorrhages | 5 | 2025 | 106 | 2.920 |
Why?
| | Time-to-Treatment | 8 | 2025 | 251 | 2.740 |
Why?
| | Hemostatics | 3 | 2025 | 64 | 2.280 |
Why?
| | Vasoconstrictor Agents | 6 | 2024 | 150 | 2.240 |
Why?
| | Cerebral Hemorrhage | 4 | 2025 | 125 | 2.100 |
Why?
| | Tranexamic Acid | 4 | 2022 | 59 | 2.090 |
Why?
| | Warfarin | 5 | 2021 | 179 | 2.070 |
Why?
| | Drug Therapy | 4 | 2026 | 84 | 2.040 |
Why?
| | Anesthetics, Local | 3 | 2026 | 104 | 2.000 |
Why?
| | Anti-Bacterial Agents | 12 | 2026 | 1923 | 1.950 |
Why?
| | Hemorrhage | 8 | 2026 | 822 | 1.890 |
Why?
| | Etomidate | 3 | 2023 | 21 | 1.870 |
Why?
| | Acute Pain | 3 | 2022 | 58 | 1.800 |
Why?
| | Factor Xa | 2 | 2025 | 36 | 1.800 |
Why?
| | Tissue Plasminogen Activator | 4 | 2022 | 248 | 1.790 |
Why?
| | Tachycardia, Supraventricular | 3 | 2023 | 49 | 1.580 |
Why?
| | Ketamine | 4 | 2023 | 137 | 1.570 |
Why?
| | Humans | 124 | 2026 | 145474 | 1.550 |
Why?
| | Critical Illness | 10 | 2026 | 900 | 1.530 |
Why?
| | Deamino Arginine Vasopressin | 2 | 2025 | 15 | 1.530 |
Why?
| | Critical Care | 8 | 2026 | 702 | 1.500 |
Why?
| | Eye | 2 | 2023 | 112 | 1.480 |
Why?
| | Retrospective Studies | 44 | 2026 | 17291 | 1.480 |
Why?
| | Fibrinolytic Agents | 6 | 2025 | 297 | 1.470 |
Why?
| | Intensive Care Units | 8 | 2022 | 924 | 1.340 |
Why?
| | Platelet Aggregation Inhibitors | 3 | 2025 | 499 | 1.260 |
Why?
| | Professional Role | 8 | 2026 | 169 | 1.220 |
Why?
| | Vitamin D Deficiency | 3 | 2019 | 190 | 1.210 |
Why?
| | Hospital Mortality | 7 | 2025 | 1038 | 1.200 |
Why?
| | Burns | 3 | 2019 | 374 | 1.170 |
Why?
| | Blood Coagulation Disorders | 2 | 2022 | 198 | 1.140 |
Why?
| | Vitamin D | 3 | 2019 | 403 | 1.090 |
Why?
| | Pyridones | 4 | 2026 | 209 | 1.080 |
Why?
| | Adrenal Insufficiency | 2 | 2020 | 31 | 1.080 |
Why?
| | Seizures | 4 | 2022 | 483 | 1.080 |
Why?
| | Pyrazoles | 5 | 2026 | 517 | 1.060 |
Why?
| | Hypnotics and Sedatives | 7 | 2025 | 222 | 1.050 |
Why?
| | Pyelonephritis | 2 | 2024 | 13 | 1.050 |
Why?
| | Stroke | 6 | 2026 | 1270 | 1.030 |
Why?
| | Hematoma | 2 | 2025 | 63 | 1.020 |
Why?
| | Neuromuscular Blocking Agents | 2 | 2025 | 28 | 0.990 |
Why?
| | Succinylcholine | 2 | 2023 | 7 | 0.990 |
Why?
| | Aged | 33 | 2026 | 26153 | 0.990 |
Why?
| | Middle Aged | 38 | 2026 | 36215 | 0.950 |
Why?
| | Infusions, Intravenous | 4 | 2025 | 428 | 0.950 |
Why?
| | Hyperkalemia | 1 | 2026 | 36 | 0.930 |
Why?
| | Potassium | 1 | 2026 | 152 | 0.930 |
Why?
| | Anti-Arrhythmia Agents | 2 | 2023 | 144 | 0.920 |
Why?
| | Anesthesia, Conduction | 1 | 2026 | 44 | 0.900 |
Why?
| | Face | 2 | 2023 | 174 | 0.890 |
Why?
| | Personality | 1 | 2026 | 129 | 0.850 |
Why?
| | Nerve Block | 1 | 2026 | 107 | 0.850 |
Why?
| | Thrombosis | 3 | 2025 | 400 | 0.820 |
Why?
| | Amyloid | 1 | 2025 | 94 | 0.820 |
Why?
| | Neuromuscular Nondepolarizing Agents | 1 | 2024 | 33 | 0.810 |
Why?
| | Deprescriptions | 1 | 2024 | 37 | 0.770 |
Why?
| | Female | 46 | 2026 | 78844 | 0.770 |
Why?
| | Norepinephrine | 2 | 2023 | 201 | 0.760 |
Why?
| | Organ Dysfunction Scores | 2 | 2020 | 55 | 0.750 |
Why?
| | Male | 43 | 2026 | 72842 | 0.750 |
Why?
| | Calcium Channel Blockers | 1 | 2023 | 166 | 0.750 |
Why?
| | Periodicals as Topic | 4 | 2021 | 209 | 0.750 |
Why?
| | Gastrointestinal Hemorrhage | 2 | 2022 | 138 | 0.740 |
Why?
| | United States | 18 | 2026 | 16098 | 0.720 |
Why?
| | Thrombelastography | 2 | 2020 | 192 | 0.720 |
Why?
| | Cycloserine | 1 | 2022 | 5 | 0.720 |
Why?
| | Heart Arrest | 3 | 2024 | 410 | 0.710 |
Why?
| | Thiamine | 1 | 2021 | 19 | 0.690 |
Why?
| | Sexually Transmitted Diseases | 1 | 2024 | 168 | 0.690 |
Why?
| | Biomedical Research | 2 | 2026 | 717 | 0.680 |
Why?
| | Triage | 3 | 2021 | 250 | 0.670 |
Why?
| | Analgesics, Non-Narcotic | 1 | 2022 | 128 | 0.650 |
Why?
| | Cerebral Intraventricular Hemorrhage | 1 | 2020 | 6 | 0.650 |
Why?
| | Spinal Cord Injuries | 1 | 2024 | 234 | 0.640 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 3 | 2026 | 345 | 0.640 |
Why?
| | Tetracaine | 1 | 2020 | 6 | 0.640 |
Why?
| | Intracranial Hemorrhage, Traumatic | 1 | 2020 | 11 | 0.640 |
Why?
| | Antihypertensive Agents | 2 | 2021 | 519 | 0.630 |
Why?
| | Ascorbic Acid | 1 | 2021 | 184 | 0.620 |
Why?
| | Oseltamivir | 1 | 2020 | 17 | 0.620 |
Why?
| | Heat Stroke | 1 | 2019 | 5 | 0.620 |
Why?
| | Analgesia | 1 | 2021 | 106 | 0.620 |
Why?
| | Vitamins | 2 | 2019 | 182 | 0.610 |
Why?
| | Thromboembolism | 1 | 2021 | 129 | 0.610 |
Why?
| | Cholesterol, HDL | 1 | 2020 | 201 | 0.610 |
Why?
| | Pain Measurement | 2 | 2021 | 561 | 0.610 |
Why?
| | Hyperlactatemia | 1 | 2019 | 3 | 0.610 |
Why?
| | Bupropion | 1 | 2020 | 48 | 0.600 |
Why?
| | After-Hours Care | 1 | 2019 | 17 | 0.600 |
Why?
| | Anti-Infective Agents | 2 | 2022 | 232 | 0.600 |
Why?
| | Adult | 30 | 2026 | 40777 | 0.600 |
Why?
| | Antifibrinolytic Agents | 1 | 2020 | 64 | 0.600 |
Why?
| | Hydrocortisone | 1 | 2021 | 298 | 0.590 |
Why?
| | Venous Thrombosis | 1 | 2021 | 196 | 0.590 |
Why?
| | Brain Ischemia | 2 | 2020 | 359 | 0.590 |
Why?
| | Autism Spectrum Disorder | 2 | 2022 | 422 | 0.590 |
Why?
| | Vasopressins | 1 | 2019 | 61 | 0.590 |
Why?
| | Time Factors | 8 | 2025 | 7123 | 0.590 |
Why?
| | Nonprescription Drugs | 1 | 2020 | 69 | 0.590 |
Why?
| | Alzheimer Disease | 2 | 2026 | 630 | 0.590 |
Why?
| | Analgesics, Opioid | 4 | 2026 | 1149 | 0.590 |
Why?
| | Carotid Stenosis | 1 | 2020 | 107 | 0.590 |
Why?
| | Bacteremia | 1 | 2021 | 222 | 0.590 |
Why?
| | Acidosis, Lactic | 1 | 2019 | 46 | 0.580 |
Why?
| | Coinfection | 1 | 2020 | 143 | 0.580 |
Why?
| | Liver Failure, Acute | 1 | 2019 | 68 | 0.580 |
Why?
| | Acetylcysteine | 1 | 2019 | 139 | 0.570 |
Why?
| | Complement C1 Inhibitor Protein | 1 | 2018 | 12 | 0.570 |
Why?
| | Dyslipidemias | 1 | 2020 | 184 | 0.560 |
Why?
| | Bradykinin | 1 | 2018 | 49 | 0.560 |
Why?
| | Urinary Tract Infections | 4 | 2025 | 210 | 0.560 |
Why?
| | Hypotension | 1 | 2019 | 127 | 0.560 |
Why?
| | Angioedema | 1 | 2018 | 16 | 0.560 |
Why?
| | Patient Care Bundles | 1 | 2018 | 29 | 0.550 |
Why?
| | Lidocaine | 1 | 2018 | 55 | 0.550 |
Why?
| | Psychoses, Substance-Induced | 1 | 2018 | 16 | 0.550 |
Why?
| | Fluid Therapy | 5 | 2019 | 155 | 0.550 |
Why?
| | Levofloxacin | 1 | 2018 | 21 | 0.550 |
Why?
| | Drug Overdose | 3 | 2019 | 374 | 0.550 |
Why?
| | Triglycerides | 1 | 2020 | 520 | 0.540 |
Why?
| | Veterans | 3 | 2025 | 1635 | 0.540 |
Why?
| | Cross Infection | 1 | 2020 | 260 | 0.540 |
Why?
| | Administration, Oral | 3 | 2026 | 866 | 0.530 |
Why?
| | Prescription Drugs | 1 | 2019 | 111 | 0.530 |
Why?
| | Anemia, Sickle Cell | 1 | 2021 | 318 | 0.520 |
Why?
| | Aged, 80 and over | 10 | 2025 | 8333 | 0.510 |
Why?
| | Venous Thromboembolism | 1 | 2021 | 328 | 0.510 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2018 | 229 | 0.510 |
Why?
| | Cohort Studies | 8 | 2025 | 6013 | 0.510 |
Why?
| | Calcium | 2 | 2023 | 1190 | 0.500 |
Why?
| | Multiple Organ Failure | 1 | 2017 | 120 | 0.490 |
Why?
| | Metabolic Syndrome | 1 | 2020 | 360 | 0.490 |
Why?
| | Cause of Death | 1 | 2019 | 470 | 0.490 |
Why?
| | Patient Care Team | 3 | 2026 | 696 | 0.470 |
Why?
| | Bone and Bones | 1 | 2019 | 317 | 0.470 |
Why?
| | Randomized Controlled Trials as Topic | 6 | 2021 | 1747 | 0.470 |
Why?
| | Vitamin K Deficiency Bleeding | 1 | 2015 | 5 | 0.460 |
Why?
| | Smoking Cessation | 1 | 2020 | 440 | 0.460 |
Why?
| | Dexmedetomidine | 3 | 2022 | 47 | 0.460 |
Why?
| | Thrombolytic Therapy | 3 | 2025 | 164 | 0.460 |
Why?
| | Intubation | 1 | 2015 | 8 | 0.460 |
Why?
| | Abdominal Abscess | 1 | 2015 | 26 | 0.450 |
Why?
| | Blood Coagulation | 2 | 2025 | 274 | 0.440 |
Why?
| | Statistics, Nonparametric | 3 | 2021 | 428 | 0.440 |
Why?
| | Designer Drugs | 1 | 2014 | 7 | 0.440 |
Why?
| | Intubation, Intratracheal | 3 | 2023 | 325 | 0.420 |
Why?
| | Heart-Assist Devices | 1 | 2020 | 568 | 0.420 |
Why?
| | BK Virus | 1 | 2014 | 18 | 0.410 |
Why?
| | Kidney Transplantation | 2 | 2026 | 712 | 0.410 |
Why?
| | Polyomavirus Infections | 1 | 2014 | 30 | 0.410 |
Why?
| | Tumor Virus Infections | 1 | 2014 | 51 | 0.410 |
Why?
| | Opportunistic Infections | 1 | 2014 | 47 | 0.410 |
Why?
| | Antiviral Agents | 1 | 2020 | 769 | 0.400 |
Why?
| | Dietary Supplements | 2 | 2019 | 583 | 0.400 |
Why?
| | Lactic Acid | 3 | 2023 | 295 | 0.400 |
Why?
| | Influenza, Human | 1 | 2020 | 624 | 0.400 |
Why?
| | Epinephrine | 2 | 2024 | 158 | 0.390 |
Why?
| | Hypertension | 2 | 2021 | 1273 | 0.390 |
Why?
| | Treatment Outcome | 9 | 2022 | 11772 | 0.380 |
Why?
| | Propensity Score | 2 | 2025 | 377 | 0.380 |
Why?
| | Risk Factors | 8 | 2026 | 10885 | 0.380 |
Why?
| | International Normalized Ratio | 3 | 2022 | 55 | 0.380 |
Why?
| | Peptides | 1 | 2018 | 998 | 0.370 |
Why?
| | Cytomegalovirus Infections | 1 | 2014 | 206 | 0.360 |
Why?
| | Recombinant Proteins | 2 | 2025 | 1368 | 0.350 |
Why?
| | Pharmacy | 2 | 2023 | 32 | 0.350 |
Why?
| | Length of Stay | 6 | 2025 | 1349 | 0.350 |
Why?
| | Respiratory Insufficiency | 1 | 2015 | 326 | 0.350 |
Why?
| | Incidence | 4 | 2021 | 2923 | 0.340 |
Why?
| | Emergency Medical Services | 1 | 2018 | 684 | 0.340 |
Why?
| | Blood Culture | 2 | 2023 | 27 | 0.320 |
Why?
| | Multivariate Analysis | 4 | 2019 | 1547 | 0.320 |
Why?
| | Patient Discharge | 5 | 2024 | 992 | 0.320 |
Why?
| | Severity of Illness Index | 4 | 2020 | 2930 | 0.310 |
Why?
| | Peer Review | 2 | 2023 | 47 | 0.300 |
Why?
| | Wounds and Injuries | 2 | 2019 | 961 | 0.300 |
Why?
| | Logistic Models | 4 | 2019 | 2134 | 0.290 |
Why?
| | Intellectual Disability | 2 | 2021 | 179 | 0.290 |
Why?
| | Patient Safety | 2 | 2026 | 356 | 0.280 |
Why?
| | Mentors | 3 | 2026 | 217 | 0.270 |
Why?
| | Hospitals | 2 | 2026 | 732 | 0.260 |
Why?
| | Neuromuscular Blockade | 2 | 2025 | 53 | 0.250 |
Why?
| | Advanced Cardiac Life Support | 2 | 2024 | 28 | 0.250 |
Why?
| | Skin Diseases, Bacterial | 1 | 2026 | 22 | 0.240 |
Why?
| | Substance-Related Disorders | 2 | 2019 | 1102 | 0.240 |
Why?
| | Soft Tissue Infections | 1 | 2026 | 40 | 0.240 |
Why?
| | Medication Reconciliation | 1 | 2026 | 32 | 0.240 |
Why?
| | Digestive System Diseases | 1 | 2026 | 28 | 0.240 |
Why?
| | Prospective Studies | 4 | 2024 | 8057 | 0.230 |
Why?
| | Personality Inventory | 1 | 2026 | 134 | 0.230 |
Why?
| | Chi-Square Distribution | 2 | 2019 | 527 | 0.230 |
Why?
| | Observational Studies as Topic | 2 | 2024 | 133 | 0.230 |
Why?
| | Postoperative Hemorrhage | 1 | 2026 | 105 | 0.220 |
Why?
| | Inappropriate Prescribing | 1 | 2026 | 66 | 0.220 |
Why?
| | Enterococcus | 1 | 2025 | 22 | 0.220 |
Why?
| | Hepatitis B Vaccines | 1 | 2025 | 43 | 0.220 |
Why?
| | Paralysis | 1 | 2025 | 69 | 0.220 |
Why?
| | Immunoglobulins | 1 | 2025 | 162 | 0.220 |
Why?
| | Structure-Activity Relationship | 1 | 2026 | 563 | 0.210 |
Why?
| | Hepatitis B | 1 | 2025 | 66 | 0.210 |
Why?
| | Molecular Structure | 1 | 2026 | 486 | 0.210 |
Why?
| | Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2024 | 43 | 0.210 |
Why?
| | Gram-Positive Bacterial Infections | 1 | 2025 | 71 | 0.210 |
Why?
| | Cephalosporins | 1 | 2024 | 45 | 0.210 |
Why?
| | Ultrasonography, Interventional | 1 | 2026 | 165 | 0.210 |
Why?
| | Awareness | 1 | 2025 | 110 | 0.210 |
Why?
| | Young Adult | 6 | 2026 | 14218 | 0.210 |
Why?
| | Administration, Intravenous | 1 | 2025 | 172 | 0.210 |
Why?
| | Spinal Cord Diseases | 1 | 2024 | 42 | 0.210 |
Why?
| | Vecuronium Bromide | 1 | 2024 | 8 | 0.210 |
Why?
| | Risk Assessment | 3 | 2020 | 3747 | 0.210 |
Why?
| | Academic Medical Centers | 2 | 2019 | 554 | 0.210 |
Why?
| | Survival Analysis | 2 | 2019 | 1374 | 0.200 |
Why?
| | Practice Guidelines as Topic | 4 | 2025 | 1581 | 0.200 |
Why?
| | Evidence-Based Medicine | 2 | 2026 | 740 | 0.200 |
Why?
| | Job Satisfaction | 1 | 2026 | 237 | 0.200 |
Why?
| | Patient Admission | 1 | 2025 | 220 | 0.200 |
Why?
| | Acute Disease | 1 | 2026 | 1036 | 0.190 |
Why?
| | Clinical Decision-Making | 1 | 2026 | 363 | 0.190 |
Why?
| | Pharmacy Residencies | 2 | 2019 | 10 | 0.190 |
Why?
| | Mass Casualty Incidents | 1 | 2023 | 50 | 0.190 |
Why?
| | Organizations | 1 | 2022 | 28 | 0.190 |
Why?
| | Epistaxis | 1 | 2022 | 17 | 0.180 |
Why?
| | Cystitis | 1 | 2022 | 24 | 0.180 |
Why?
| | Exoribonucleases | 1 | 2023 | 43 | 0.180 |
Why?
| | Sex Offenses | 1 | 2025 | 196 | 0.180 |
Why?
| | Vitamin K | 1 | 2022 | 46 | 0.180 |
Why?
| | Benzaldehydes | 1 | 2021 | 11 | 0.180 |
Why?
| | Hemoglobin, Sickle | 1 | 2021 | 20 | 0.180 |
Why?
| | Disaster Planning | 1 | 2023 | 103 | 0.180 |
Why?
| | Blood Coagulation Tests | 1 | 2022 | 72 | 0.180 |
Why?
| | Troponin | 1 | 2021 | 50 | 0.180 |
Why?
| | Microtubule-Associated Proteins | 1 | 2023 | 194 | 0.170 |
Why?
| | Myelitis, Transverse | 1 | 2021 | 4 | 0.170 |
Why?
| | Propofol | 1 | 2022 | 85 | 0.170 |
Why?
| | Hearing Loss, Bilateral | 1 | 2021 | 13 | 0.170 |
Why?
| | Hearing Loss, Sudden | 1 | 2021 | 12 | 0.170 |
Why?
| | Sexual Harassment | 1 | 2021 | 29 | 0.170 |
Why?
| | Megalencephaly | 1 | 2021 | 20 | 0.170 |
Why?
| | Pharmacies | 1 | 2021 | 40 | 0.170 |
Why?
| | Angiotensin II | 1 | 2021 | 101 | 0.170 |
Why?
| | Pharmaceutical Services | 1 | 2021 | 76 | 0.170 |
Why?
| | Cardiopulmonary Resuscitation | 1 | 2024 | 338 | 0.170 |
Why?
| | Pyrazines | 1 | 2021 | 94 | 0.160 |
Why?
| | Cerebral Hemorrhage, Traumatic | 1 | 2020 | 2 | 0.160 |
Why?
| | Hematoma, Subdural, Intracranial | 1 | 2020 | 2 | 0.160 |
Why?
| | Arthrogryposis | 1 | 2020 | 17 | 0.160 |
Why?
| | Bibliometrics | 1 | 2021 | 66 | 0.160 |
Why?
| | Subarachnoid Hemorrhage, Traumatic | 1 | 2020 | 5 | 0.160 |
Why?
| | Prader-Willi Syndrome | 1 | 2020 | 33 | 0.160 |
Why?
| | Anesthesia, Local | 1 | 2020 | 26 | 0.160 |
Why?
| | Substance Withdrawal Syndrome | 1 | 2022 | 185 | 0.160 |
Why?
| | Electrocardiography | 1 | 2023 | 665 | 0.160 |
Why?
| | Antipsychotic Agents | 1 | 2022 | 211 | 0.160 |
Why?
| | Mentoring | 1 | 2023 | 165 | 0.160 |
Why?
| | Creatinine | 1 | 2021 | 515 | 0.150 |
Why?
| | Biopsy, Needle | 1 | 2020 | 185 | 0.150 |
Why?
| | United States Department of Veterans Affairs | 1 | 2024 | 778 | 0.150 |
Why?
| | Rehydration Solutions | 1 | 2019 | 9 | 0.150 |
Why?
| | Craniocerebral Trauma | 1 | 2022 | 178 | 0.150 |
Why?
| | Thyroid Nodule | 1 | 2020 | 57 | 0.150 |
Why?
| | Ambulances | 1 | 2019 | 52 | 0.150 |
Why?
| | Drug Approval | 1 | 2020 | 93 | 0.150 |
Why?
| | Mass Screening | 2 | 2018 | 1360 | 0.150 |
Why?
| | Quality-Adjusted Life Years | 1 | 2019 | 123 | 0.150 |
Why?
| | Anticonvulsants | 1 | 2022 | 246 | 0.150 |
Why?
| | Burnout, Professional | 1 | 2026 | 488 | 0.150 |
Why?
| | Prognosis | 2 | 2020 | 4316 | 0.150 |
Why?
| | Vitamin D-Binding Protein | 1 | 2019 | 16 | 0.150 |
Why?
| | Respiration, Artificial | 2 | 2021 | 713 | 0.150 |
Why?
| | Surveys and Questionnaires | 4 | 2026 | 6066 | 0.140 |
Why?
| | Atrial Fibrillation | 2 | 2022 | 558 | 0.140 |
Why?
| | Patient Readmission | 1 | 2025 | 769 | 0.140 |
Why?
| | United States Food and Drug Administration | 1 | 2020 | 208 | 0.140 |
Why?
| | Prescription Drug Misuse | 1 | 2019 | 52 | 0.140 |
Why?
| | APACHE | 2 | 2016 | 68 | 0.140 |
Why?
| | Arterial Pressure | 1 | 2019 | 134 | 0.140 |
Why?
| | Kallikreins | 1 | 2018 | 26 | 0.140 |
Why?
| | Histamine Antagonists | 1 | 2018 | 21 | 0.140 |
Why?
| | Drug Therapy, Combination | 1 | 2021 | 1044 | 0.140 |
Why?
| | Sodium Chloride | 1 | 2019 | 138 | 0.140 |
Why?
| | Cost Savings | 1 | 2019 | 86 | 0.140 |
Why?
| | Students, Pharmacy | 1 | 2019 | 96 | 0.140 |
Why?
| | Hemodynamics | 1 | 2023 | 1118 | 0.140 |
Why?
| | Pelvic Bones | 1 | 2020 | 134 | 0.140 |
Why?
| | Alcoholism | 2 | 2022 | 822 | 0.140 |
Why?
| | ROC Curve | 1 | 2020 | 617 | 0.140 |
Why?
| | Pain Management | 1 | 2022 | 410 | 0.140 |
Why?
| | Renin-Angiotensin System | 1 | 2018 | 80 | 0.140 |
Why?
| | Rivaroxaban | 1 | 2020 | 271 | 0.130 |
Why?
| | Medicare | 2 | 2021 | 903 | 0.130 |
Why?
| | Neurodevelopmental Disorders | 1 | 2021 | 227 | 0.130 |
Why?
| | Patient Acceptance of Health Care | 1 | 2025 | 881 | 0.130 |
Why?
| | Registries | 2 | 2024 | 2406 | 0.130 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2026 | 1419 | 0.130 |
Why?
| | Reference Values | 1 | 2019 | 798 | 0.130 |
Why?
| | California | 1 | 2019 | 471 | 0.130 |
Why?
| | Educational Status | 1 | 2019 | 466 | 0.130 |
Why?
| | Disease Management | 1 | 2021 | 653 | 0.130 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2019 | 2028 | 0.130 |
Why?
| | Aspirin | 1 | 2020 | 406 | 0.130 |
Why?
| | Administration, Intranasal | 1 | 2017 | 94 | 0.130 |
Why?
| | Midazolam | 1 | 2017 | 73 | 0.120 |
Why?
| | Plasma | 1 | 2018 | 223 | 0.120 |
Why?
| | Patient Transfer | 1 | 2019 | 211 | 0.120 |
Why?
| | Algorithms | 1 | 2024 | 1845 | 0.120 |
Why?
| | Vaccination | 1 | 2025 | 1426 | 0.120 |
Why?
| | Resuscitation | 1 | 2019 | 310 | 0.120 |
Why?
| | Cost-Benefit Analysis | 1 | 2019 | 639 | 0.120 |
Why?
| | Socioeconomic Factors | 1 | 2021 | 1323 | 0.120 |
Why?
| | International Classification of Diseases | 1 | 2017 | 150 | 0.120 |
Why?
| | Gastrointestinal Diseases | 1 | 2018 | 221 | 0.120 |
Why?
| | Organizational Policy | 1 | 2016 | 78 | 0.120 |
Why?
| | Biomarkers | 2 | 2020 | 4295 | 0.120 |
Why?
| | Health Care Costs | 1 | 2019 | 425 | 0.120 |
Why?
| | Community-Acquired Infections | 1 | 2018 | 177 | 0.120 |
Why?
| | Waiting Lists | 1 | 2018 | 266 | 0.120 |
Why?
| | Double-Blind Method | 1 | 2021 | 2062 | 0.120 |
Why?
| | Naloxone | 1 | 2017 | 131 | 0.110 |
Why?
| | Fentanyl | 1 | 2017 | 128 | 0.110 |
Why?
| | Chicago | 1 | 2015 | 62 | 0.110 |
Why?
| | Injections, Intravenous | 1 | 2015 | 197 | 0.110 |
Why?
| | Publications | 1 | 2015 | 47 | 0.110 |
Why?
| | Motivation | 1 | 2019 | 600 | 0.110 |
Why?
| | Fractures, Bone | 1 | 2020 | 428 | 0.110 |
Why?
| | Practice Patterns, Physicians' | 1 | 2024 | 1371 | 0.110 |
Why?
| | Ergocalciferols | 1 | 2014 | 14 | 0.110 |
Why?
| | Magnetic Resonance Imaging | 2 | 2025 | 3904 | 0.110 |
Why?
| | Sex Distribution | 1 | 2015 | 387 | 0.100 |
Why?
| | Tomography, X-Ray Computed | 1 | 2025 | 2769 | 0.100 |
Why?
| | Cholecalciferol | 1 | 2014 | 61 | 0.100 |
Why?
| | Chromium | 1 | 2013 | 17 | 0.100 |
Why?
| | Michigan | 1 | 2014 | 134 | 0.100 |
Why?
| | Brain Concussion | 1 | 2022 | 644 | 0.100 |
Why?
| | Manganese | 1 | 2013 | 55 | 0.100 |
Why?
| | Selenium | 1 | 2013 | 50 | 0.100 |
Why?
| | Nutritional Requirements | 1 | 2013 | 78 | 0.100 |
Why?
| | Copper | 1 | 2013 | 119 | 0.090 |
Why?
| | Research Design | 1 | 2019 | 1137 | 0.090 |
Why?
| | Parenteral Nutrition | 1 | 2013 | 102 | 0.090 |
Why?
| | Analysis of Variance | 1 | 2015 | 1300 | 0.090 |
Why?
| | Pneumonia | 1 | 2018 | 636 | 0.090 |
Why?
| | Electronic Health Records | 2 | 2019 | 1196 | 0.080 |
Why?
| | Iron | 1 | 2013 | 357 | 0.080 |
Why?
| | Wound Healing | 1 | 2013 | 355 | 0.080 |
Why?
| | Zinc | 1 | 2013 | 306 | 0.080 |
Why?
| | Mental Disorders | 1 | 2019 | 1163 | 0.080 |
Why?
| | Societies, Medical | 2 | 2026 | 899 | 0.080 |
Why?
| | Primary Health Care | 1 | 2021 | 1735 | 0.080 |
Why?
| | Antioxidants | 1 | 2013 | 550 | 0.080 |
Why?
| | Quality Improvement | 1 | 2018 | 1295 | 0.080 |
Why?
| | Immunosuppressive Agents | 1 | 2014 | 838 | 0.070 |
Why?
| | Adolescent | 3 | 2026 | 22529 | 0.070 |
Why?
| | Pregnancy | 1 | 2022 | 7202 | 0.070 |
Why?
| | Sex Factors | 1 | 2014 | 2105 | 0.070 |
Why?
| | Child | 4 | 2022 | 22707 | 0.070 |
Why?
| | Age Factors | 1 | 2014 | 3342 | 0.060 |
Why?
| | Cross-Sectional Studies | 3 | 2026 | 5904 | 0.060 |
Why?
| | Fasciitis, Necrotizing | 1 | 2026 | 16 | 0.060 |
Why?
| | Cellulitis | 1 | 2026 | 54 | 0.060 |
Why?
| | Potentially Inappropriate Medication List | 1 | 2026 | 17 | 0.060 |
Why?
| | Animals | 2 | 2022 | 38030 | 0.060 |
Why?
| | Abscess | 1 | 2026 | 77 | 0.060 |
Why?
| | Carboxylic Ester Hydrolases | 1 | 2025 | 24 | 0.060 |
Why?
| | Drainage | 1 | 2026 | 185 | 0.060 |
Why?
| | Urinalysis | 1 | 2025 | 83 | 0.050 |
Why?
| | Neurology | 1 | 2026 | 116 | 0.050 |
Why?
| | Preoperative Care | 1 | 2026 | 380 | 0.050 |
Why?
| | Infant, Newborn | 1 | 2015 | 6447 | 0.050 |
Why?
| | Shock, Cardiogenic | 1 | 2023 | 65 | 0.050 |
Why?
| | Citric Acid | 1 | 2023 | 33 | 0.050 |
Why?
| | Peer Review, Research | 1 | 2023 | 36 | 0.050 |
Why?
| | Hypocalcemia | 1 | 2023 | 39 | 0.050 |
Why?
| | Shock | 1 | 2023 | 110 | 0.050 |
Why?
| | Diphenhydramine | 1 | 2022 | 36 | 0.050 |
Why?
| | Fluoroquinolones | 1 | 2022 | 44 | 0.050 |
Why?
| | beta-Lactamases | 1 | 2022 | 53 | 0.040 |
Why?
| | Patient Satisfaction | 1 | 2026 | 709 | 0.040 |
Why?
| | Inpatients | 1 | 2026 | 553 | 0.040 |
Why?
| | Chronic Pain | 1 | 2026 | 291 | 0.040 |
Why?
| | Drug Resistance, Bacterial | 1 | 2022 | 185 | 0.040 |
Why?
| | Microbial Sensitivity Tests | 1 | 2022 | 364 | 0.040 |
Why?
| | Peer Group | 1 | 2023 | 253 | 0.040 |
Why?
| | Guideline Adherence | 1 | 2025 | 586 | 0.040 |
Why?
| | Gender Identity | 1 | 2021 | 128 | 0.040 |
Why?
| | Syndrome | 1 | 2021 | 381 | 0.040 |
Why?
| | Intrinsically Disordered Proteins | 1 | 2020 | 42 | 0.040 |
Why?
| | Education, Pharmacy, Graduate | 1 | 2019 | 13 | 0.040 |
Why?
| | Emotional Intelligence | 1 | 2019 | 13 | 0.040 |
Why?
| | Chronic Disease | 1 | 2026 | 1808 | 0.040 |
Why?
| | Hospitals, Psychiatric | 1 | 2019 | 29 | 0.040 |
Why?
| | Blood Transfusion | 1 | 2023 | 409 | 0.040 |
Why?
| | Back Pain | 1 | 2019 | 52 | 0.040 |
Why?
| | Chest Pain | 1 | 2019 | 99 | 0.040 |
Why?
| | Medically Uninsured | 1 | 2019 | 132 | 0.040 |
Why?
| | Brain Injuries, Traumatic | 1 | 2025 | 453 | 0.040 |
Why?
| | Renal Replacement Therapy | 1 | 2019 | 100 | 0.040 |
Why?
| | Alcoholic Intoxication | 1 | 2019 | 76 | 0.040 |
Why?
| | Abdominal Pain | 1 | 2019 | 149 | 0.030 |
Why?
| | Bias | 1 | 2019 | 197 | 0.030 |
Why?
| | Escherichia coli | 1 | 2022 | 835 | 0.030 |
Why?
| | Education, Pharmacy | 1 | 2019 | 120 | 0.030 |
Why?
| | Health Services Needs and Demand | 1 | 2019 | 280 | 0.030 |
Why?
| | Physicians | 1 | 2026 | 955 | 0.030 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2020 | 456 | 0.030 |
Why?
| | Disability Evaluation | 1 | 2019 | 310 | 0.030 |
Why?
| | Laboratories, Hospital | 1 | 2016 | 14 | 0.030 |
Why?
| | Nervous System Diseases | 1 | 2019 | 286 | 0.030 |
Why?
| | Health Personnel | 1 | 2023 | 754 | 0.030 |
Why?
| | Early Medical Intervention | 1 | 2016 | 62 | 0.030 |
Why?
| | Telephone | 1 | 2016 | 177 | 0.030 |
Why?
| | Early Diagnosis | 1 | 2016 | 251 | 0.030 |
Why?
| | Medicaid | 1 | 2019 | 467 | 0.030 |
Why?
| | Prevalence | 1 | 2022 | 2865 | 0.030 |
Why?
| | Recovery of Function | 1 | 2019 | 716 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2019 | 1508 | 0.030 |
Why?
| | Internet | 1 | 2019 | 689 | 0.030 |
Why?
| | Proteins | 1 | 2020 | 1023 | 0.030 |
Why?
| | Mortality | 1 | 2016 | 378 | 0.030 |
Why?
| | Health Status | 1 | 2019 | 832 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2019 | 2121 | 0.020 |
Why?
| | Hospitals, Teaching | 1 | 2014 | 120 | 0.020 |
Why?
| | Tertiary Care Centers | 1 | 2014 | 195 | 0.020 |
Why?
| | Parents | 1 | 2021 | 1403 | 0.020 |
Why?
| | Phenotype | 1 | 2020 | 3155 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2019 | 3623 | 0.020 |
Why?
| | Acute Kidney Injury | 1 | 2019 | 875 | 0.020 |
Why?
| | Kidney Failure, Chronic | 1 | 2014 | 599 | 0.020 |
Why?
|
|
Rech's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|